文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛心脑血管急症

血管加压素联合儿茶酚胺类升压药与单用儿茶酚胺对分布性休克患者心房颤动的影响:系统评价与Meta分析

Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在分布性休克患者中,与单用儿茶酚胺类升压药相比,联合血管加压素与心房颤动风险降低相关(RR 0.77)。

该系统评价与Meta分析纳入23项随机临床试验、共3088例分布性休克患者,比较血管加压素联合儿茶酚胺类升压药与单用儿茶酚胺类升压药。主要终点心房颤动风险在联合组更低(RR 0.77,95%CI 0.67-0.88),证据质量高。病死率总体RR 0.89(95%CI 0.82-0.97),但限于低偏倚风险试验时RR 0.96(95%CI 0.84-1.11)。肾脏替代治疗总体RR 0.74(95%CI 0.51-1.08),低偏倚风险试验中RR 0.70(95%CI 0.53-0.92,交互作用P=0.77)。其他结局合并风险无显著差异。

要点

  • 分布性休克患者中,血管加压素联合儿茶酚胺类升压药较单用儿茶酚胺类升压药降低心房颤动风险(RR 0.77,95%CI 0.67-0.88),为高质量证据。
  • 病死率总体RR 0.89(95%CI 0.82-0.97),但限于低偏倚风险试验时RR 0.96(95%CI 0.84-1.11),关联不稳定。
  • 肾脏替代治疗总体RR 0.74(95%CI 0.51-1.08),低偏倚风险试验中RR 0.70(95%CI 0.53-0.92,交互作用P=0.77)。
  • 其他结局(心肌损伤、室性心律失常、卒中、ICU及住院时间)合并风险无显著差异。

适用人群与场景

  • 分布性休克患者,多因严重感染导致血管过度扩张。

研究设计与关键结果

  • 系统评价与Meta分析纳入23项随机临床试验,共3088例患者,平均年龄61.1岁(标准差14.2),女性占45.3%。
  • 主要终点心房颤动:联合血管加压素组较单用儿茶酚胺组风险更低(RR 0.77,95%CI 0.67-0.88;风险差-0.06,95%CI -0.13至0.01)。
  • 病死率:总体RR 0.89(95%CI 0.82-0.97;风险差-0.04,95%CI -0.07至0.00);限于低偏倚风险试验时RR 0.96(95%CI 0.84-1.11)。
  • 肾脏替代治疗:总体RR 0.74(95%CI 0.51-1.08;风险差-0.07,95%CI -0.12至-0.01);限于低偏倚风险试验时RR 0.70(95%CI 0.53-0.92,交互作用P=0.77)。
  • 其他结局(心肌损伤、室性心律失常、卒中、ICU及住院时间)合并风险无显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入23项随机临床试验。
  • 主要终点心房颤动为高质量证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在分布性休克患者中,与单用儿茶酚胺类升压药相比,联合血管加压素与较低的心房颤动风险相关,可据此权衡升压药选择。
  • 病死率和肾脏替代治疗等次要结局的关联在不同分析中不一致,不能据此推荐常规联合血管加压素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Vasopressin is an alternative to catecholamine vasopressors for patients with distributive shock-a condition due to excessive vasodilation, most frequently from severe infection. Blood pressure support with a noncatecholamine vasopressor may reduce stimulation of adrenergic receptors and decrease myocardial oxygen demand. Atrial fibrillation is common with catecholamines and is associated with adverse events, including mortality and increased length of stay (LOS).

OBJECTIVES: To determine whether treatment with vasopressin + catecholamine vasopressors compared with catecholamine vasopressors alone was associated with reductions in the risk of adverse events.

DATA SOURCES: MEDLINE, EMBASE, and CENTRAL were searched from inception to February 2018. Experts were asked and meta-registries searched to identify ongoing trials.

STUDY SELECTION: Pairs of reviewers identified randomized clinical trials comparing vasopressin in combination with catecholamine vasopressors to catecholamines alone for patients with distributive shock.

DATA EXTRACTION AND SYNTHESIS: Two reviewers abstracted data independently. A random-effects model was used to combine data.

MAIN OUTCOMES AND MEASURES: The primary outcome was atrial fibrillation. Other outcomes included mortality, requirement for renal replacement therapy (RRT), myocardial injury, ventricular arrhythmia, stroke, and LOS in the intensive care unit and hospital. Measures of association are reported as risk ratios (RRs) for clinical outcomes and mean differences for LOS.

RESULTS: Twenty-three randomized clinical trials were identified (3088 patients; mean age, 61.1 years [14.2]; women, 45.3%). High-quality evidence supported a lower risk of atrial fibrillation associated with vasopressin treatment (RR, 0.77 [95% CI, 0.67 to 0.88]; risk difference [RD], -0.06 [95% CI, -0.13 to 0.01]). For mortality, the overall RR estimate was 0.89 (95% CI, 0.82 to 0.97; RD, -0.04 [95% CI, -0.07 to 0.00]); however, when limited to trials at low risk of bias, the RR estimate was 0.96 (95% CI, 0.84 to 1.11). The overall RR estimate for RRT was 0.74 (95% CI, 0.51 to 1.08; RD, -0.07 [95% CI, -0.12 to -0.01]). However, in an analysis limited to trials at low risk of bias, RR was 0.70 (95% CI, 0.53 to 0.92, P for interaction = .77). There were no significant differences in the pooled risks for other outcomes.

CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the addition of vasopressin to catecholamine vasopressors compared with catecholamines alone was associated with a lower risk of atrial fibrillation. Findings for secondary outcomes varied.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29801010. doi:10.1001/jama.2018.4528

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。